China Acute Toxicity LD50 Study Supplier & Suppliers

Precision In Vivo Toxicological Profiling, Regulatory Safety Dossiers, and CDMO Scaling for Global Botanical, Pharmaceutical, and Nutraceutical Enterprises.

Integrated CRO Solutions

Core Preclinical & Extraction Capabilities

Explore our validated analytical pipelines, toxicity assays, and OEM manufacturing services compliant with international regulatory dossiers.

ODM Study and evaluation of botanical potency

ODM Study and evaluation of the potency of the botanical active ingredient(s) from different seasons and different origins. Manufacturer, Suppliers

View Details
ODM Clinic study Phase1-Phase4

ODM Clinic study (Phase1 - Phase 4） Manufacturer, Suppliers

View Details
OEM Animal study

OEM Animal study Supplier, Suppliers

View Details
Analysis methods of active ingredients

China Establishment of analysis methods of active ingredient(s) Supplier, Suppliers

View Details
Screening of active ingredients of plants

China Screening of the active ingredient(s) of plants Manufacturer, Manufacturers

View Details
OEM In Vitro Test Research Service

OEM In Vitro Test /Research Service Manufacturers, Suppliers

View Details
Acute Toxicity LD50 Study Protocols

China Acute Toxicity LD50 Study & Preclinical Safety Assessment Manufacturer, Suppliers

View Details
Natural Herbal Formulation Research Service

Natural Formulation Research & Commercial CDMO Processing Supplier, Suppliers

View Details
Authoritative Science & Global Compliance

Acute Toxicity (LD50) Study: The Fundamental Safety Benchmark

Providing definitive Median Lethal Dose toxicological data under GLP compliance, transforming raw pharmacological potency into internationally accepted risk-classification profiles.

The determination of acute toxicity, historically quantified through the Median Lethal Dose (LD50), serves as the decisive checkpoint in preclinical pharmacology, chemical hazard categorization, and botanical drug registration. As international regulatory bodies such as the US FDA, EMA, OECD, and NMPA enforce increasingly stringent standards on active botanical extracts, synthetic small molecules, and herbal formulations, accurate acute toxicological assessments provide the quantitative foundation for calculating therapeutic indexes, maximum tolerated doses (MTD), and subsequent sub-acute and chronic dosing intervals. MedGence (Yineng Pharma), backed by over 14 years of dedicated botanical pharmacology, operates as a high-authority CRO and CDMO based in Changsha, Hunan, bridging the gap between classical bio-resources and verifiable preclinical intelligence.

OECD 423 / 425 Methodologies

We deploy modern Acute Toxic Class (OECD 423) and Up-and-Down (OECD 425) methodologies, drastically reducing experimental animal usage while deriving precise statistical confidence intervals for GHS hazard tier classifications.

Systemic Organ Histopathology

Our toxicological investigations go beyond basic survival curves. Full necropsy, gross organ inspection, and microscopic histopathological examination evaluate reversible vs. irreversible damage to hepatorenal systems.

Dynamic Toxicokinetics (TK)

Correlating high-dose acute exposure with peak serum concentration (Cmax) and area under the curve (AUC), establishing clinical margins of safety essential for Investigational New Drug (IND) applications.

Industrial Superiority

The Strategic Edge of Sourcing Acute Toxicity Studies from China

How China's centralized biomedical clusters, high-purity isolation facilities, and cost efficiencies accelerate global R&D pipelines.

End-to-End CRO-CDMO Pipeline

Unlike isolated testing labs, Chinese suppliers like MedGence integrate compound screening, analytical standardization (HPLC/HPTLC/GC), LD50 profiling, and pilot manufacturing within one closed-loop facility.

Rapid Protocol Execution

Leveraging state-of-the-art animal research vivariums and established in-house colony protocols, study initiation times are reduced from months to under 10 business days, expediting commercial go-to-market decisions.

Economies of Scale & Capital Efficiency

Global sponsors benefit from a 40–60% reduction in toxicology budget expenditure compared to Western equivalents, without compromising GLP standards, regulatory scrutiny, or analytical precision.

14+
Years Dedicated Natural Medicine R&D
300+
Senior Research Scientists & Toxicologists
83
Classic TCM Formulations Standardized
~400
Herbal Active Quality Specs Established
Future-Proof Science

Emerging Trends in Acute Toxicity and Safety Testing

How the 3Rs principle, AI computational predictive modeling, and phytomedicine fingerprinting are transforming modern toxicology.

Refinement via 3Rs

Global adoption of the Replacement, Reduction, and Refinement framework. Traditional classical LD50 is replaced by modern sequential step protocols, minimizing animal subject stress while maximizing data granularity.

AI Predictive In Silico Toxicology

Machine learning platforms pre-screen chemical structure matrices to predict reactive metabolites, genotoxic substructures, and preliminary lethal dose windows prior to wet-lab biological intervention.

High-Resolution Fingerprinting

Botanical matrices contain complex multi-component synergies. Coupling acute toxicity outcomes with HPLC-MS and GC-MS fingerprint standardizations ensures batch-specific toxicity is traceably attributed to concrete chemical profiles.

Cross-Border Mutual Acceptance

Harmonization under the OECD Mutual Acceptance of Data (MAD) framework enables toxicity studies performed in Chinese accredited laboratories to be directly utilized across North American, European, and Asian drug dossiers.

Sector Applications

Localized Application Scenarios Across Target Sectors

From novel dietary compounds to agrochemical registrations, our LD50 toxicological protocols deliver concrete safety boundaries.

Target Sector Primary Study Scope Typical Test Route Key Regulatory Objective
Botanical Drugs (IND / NDA) Acute oral systemic toxicity, target organ determination, MTD determination Oral Gavage (PO), Intraperitoneal (IP) Establish starting human clinical dose, Phase I safety dossier support
Dietary Supplements / NDI Acute tolerance, GHS hazard category classification, acute toxicity index Oral (PO in single limit dose 2000-5000 mg/kg) Substantiate GRAS notices, EFSA Novel Food authorization, safety dossiers
Functional Cosmetics & Topical Acute dermal toxicity (LD50), dermal irritation/corrosion, phototoxicity Dermal Topical Application Cosmetic Ingredient Safety Assessment (INCI registration, EU Annex compliance)
Specialty Fine Chemicals & APIs Systemic acute toxicity classification, SDS hazard statements Oral, Dermal, Inhalation Global REACH registration, transport classification, workplace exposure limits
Procurement Strategy

Macro Industry Solutions & Global Procurement Requirements

Evaluating research integrity, intellectual property protection, and operational continuity when choosing an outsourced toxicology CRO.

Confidentiality & IP Protection

Global pharmaceutical sponsors require ironclad confidentiality frameworks. We conduct research under strict NDA boundaries, guaranteeing that active compound formulas, extraction processes, and proprietary data remain non-disclosed intellectual property.

Unbroken Audit Trails & Raw Data Integrity

Data integrity is paramount for international submission. Our testing facilities maintain digitized audit trails, automated environmental vivarium logs, and GLP-validated analytical reporting capable of withstanding strict regulatory reviews.

Translational Scale-up to CDMO Supply

Once safety and LD50 profiles are validated, transitioning to commercial batch manufacturing often causes delays. MedGence's pilot plant and managed industrial facilities seamlessly transition formulations to bulk CDMO delivery.

Technical Clarity

Frequently Asked Questions (FAQ)

In-depth responses regarding acute toxicity protocols, test timelines, sample requirements, and global regulatory submissions.

What is the standard turnaround time for an acute oral toxicity study?
A standard acute oral toxicity study (e.g., OECD 423 or OECD 425) typically requires 3 to 5 weeks from sample receipt and protocol finalization to provisional report delivery. This covers preliminary range-finding, a 14-day observation period, scheduled body weight assessments, gross necropsy, and comprehensive toxicological documentation.
Can acute toxicity testing replace sub-chronic repeated dose studies?
No. Acute toxicity studies measure adverse reactions occurring immediately or shortly after single or multiple doses administered within 24 hours. While crucial for hazard identification and establishing starting doses for sub-chronic (28-day or 90-day) repeated-dose studies, it does not replace evaluations of chronic organ accumulation.
How much sample material is typically needed for an LD50 study?
Material requirements depend on compound solubility, route of administration, and anticipated toxicity tier. For standard rodent acute oral studies under OECD 423/425, approximately 20g to 50g of characterized active ingredient or extract powder is required to cover formulation trials, range-finding, and limit dosing up to 2000 mg/kg or 5000 mg/kg.
Are MedGence toxicity studies accepted by Western regulatory authorities?
Yes. Our preclinical toxicology study protocols strictly adhere to international test guidelines (OECD, ICH, ISO 10993) and Good Laboratory Practice (GLP) management systems. Studies can be structured to support IND/NDA submissions, NDI petitions, and REACH hazard dossier requirements globally.
Commercial CDMO & Supply

Preclinical Pipeline & Scaled Manufacturing Solutions

Advance your project seamlessly from validated acute toxicity data into full-scale CDMO dosage formulation and supply.

Botanical active ingredient potency ODM

ODM Study and evaluation of the potency of the botanical active ingredient(s) from different seasons and different origins. Manufacturer, Suppliers

View Details
ODM Clinic study Phase1 to Phase 4

ODM Clinic study (Phase1 - Phase 4） Manufacturer, Suppliers

View Details
OEM Preclinical Animal Study

OEM Animal study Supplier, Suppliers

View Details
Analysis methods development

China Establishment of analysis methods of active ingredient(s) Supplier, Suppliers

View Details
Bioactive botanical screening

China Screening of the active ingredient(s) of plants Manufacturer, Manufacturers

View Details
In Vitro toxicology screening

OEM In Vitro Test /Research Service Manufacturers, Suppliers

View Details
Botanical active CDMO OEM production

Contract Manufacturing (OEM) for Botanical Active Ingredients Manufacturer, Suppliers

View Details
Finished formulation CDMO supply

Contract Manufacturing (OEM/CDMO) for Finished Products Supplier, Suppliers

View Details